May. 11, 2021

Dr. Dagan and Dr. Barda developed several evaluation models, under the supervision of Prof. Eitan Bachmat, allowing for efficient decision making while fighting COVID-19 worldwide.

Earlier on in the pandemic, before COVID-19 individual-level data were available, Noam and Noa were part of a team that used a recently published recalibration procedure to adapt a model for severe respiratory infections to identify patients likely to experience severe COVID-19 if infected. This model was later validated on COVID-19 data and was found to provide excellent performance. It was used for months within Clalit Health Services to stratify patient risk so as to properly allocate limited resources for the most high-risk patients.

Link to article

Later, when individual-level data became available, they developed a simple risk-score based model for the general population. This model allowed persons to evaluate their own risk using a simple algorithm, and to take appropriate measures to protect themselves if they were found at high risk. This model was adopted by the Israeli Ministry of Health as part of its national guidelines for fighting COVID-19.

Link to article

Most recently, Noam and Noa were the first authors on a paper that evaluated the effectiveness of the Pfizer SARS-CoV-2 vaccine using a retrospective cohort based on Clalit Health Services' data. The evaluation found the vaccine to be very effective across a wide range of subgroups and outcomes and was widely published internationally.

Link to article

Link to lecture given as part of the Faculty of Natural Sciences Dean's Podium

Dr. Noa Dagan and Dr. Noam Barda recently completed their Ph.D studies in the Department of Computer Science under the supervision of Prof. Eitan Bachmat, together with Prof. Ran Balicer (mutual advisory for Noa) and Prof. Nadav Davidovitch (mutual advisory for Noam), from the Faculty of Health Sciences.

Dr. Dagan currently serves as Director of data and AI-driven medicine at the Clalit Research Institute and Dr. Barda serves as Head of epidemiology and research at Clalit Research Institute. Both are postdoctoral fellows in the Department of Biomedical Informatics (DBMI), Harvard Medical School.​

​​Noa Dagan2.jpg
Dr. Noa Dagan
Dr. Noam Barda